Abstract:Prospective tumor pH-responsive and charge-convertible nanoparticles have been utilized to reduce side effects and improve the active tumor-targeting ability and nuclear/cytoplasmic localization of chemo- and gene therapeutics for the treatment of head and neck cancer (HNC). Oxaliplatin (Oxa) is a third-generation platinum compound that prevents DNA replication. miR-320 may regulate cancer cell apoptosis, resistance, and progression. Innovative nanoparticles incorporating miR-320 and Oxa were modified with a ligand, cell-penetrating peptide, and nucleus-targeted peptide. The nanoparticles were coated with a charge/size-tunable shield to prevent peptide degradation and decoated at acidic tumor sites to expose peptides for active targeting. Results indicated that the designed nanoparticles exhibited a uniform size and satisfactory drug encapsulation efficiency. The nanoparticles displayed the pH-responsive release and uptake of Oxa and miR-320 into human tongue squamous carcinoma SAS cells. The nanoparticles successfully delivered Oxa and miR-320 to the nucleus and cytoplasm, respectively. This work is the first to demonstrate the concurrent intracellular modulation of the NRP1/Rac1 , PI3K/Akt/mTOR , GSK-3β/FOXM1/β-catenin , P-gp/MRPs,KRAS/Erk/Oct4/Yap1 , and N-cadherin/Vimentin/Slug pathways to inhibit the growth, progression, and multidrug resistance of cancer cells. In SAS-bearing mice, co-treatment with Oxa- and miR-320-loaded nanoparticles exhibited superior antitumor efficacy and remarkably decreased Oxa-associated toxicities. The nucleus/cytoplasm-localized nanoparticles with a tumor pH-sensitive and size/charge-adjustable coating may be a useful combinatorial spatiotemporal nanoplatform for nucleic acids and chemotherapeutics to achieve maximum therapeutic safety and efficacy against HNC. Statement of significance : Innovative nanoparticles incorporating miR-320 and oxaliplatin were modified with a ligand, cell-penetrating peptide, and nucleus-targeted peptide. The tumor pH-sensitive and charge/size-adjustable shield of polyglutamic acid–PEG protected against peptide degradation during systemic circulation. This work represents the first example of the concurrent intracellular modulation of the NRP1/Rac1, PI3K/Akt/mTOR,GSK-3β/FOXM1/β-catenin, P-gp/MRPs, KRAS/Erk/Oct4/Yap1, and N-cadherin/Vimentin/Slug pathways to inhibit cancer cell growth, cancer cell progression, and multidrug resistance simultaneously. The versatile nanoparticles with a tumor pH-functionalized coating could deliver chemotherapeutics and miRNA to the nucleus/cytoplasm. The nanoparticles successfully reduced chemotherapy-associated toxicities and maximized the antitumor efficacy of combinatorial therapy against head and neck cancer.

Nanoformulation of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for siRNA targeting HIF-1α for nasopharyngeal carcinoma therapy.

Delivery of siRNA targeting HIF-1 alpha loaded chitosan modified D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-glycolide) nanoparticles into nasopharyngeal carcinoma cell to improve the therapeutic efficacy of cisplatin

Transferrin-targeting Redox Hyperbranched Poly(amido Amine)-Functionalized Graphene Oxide for Sensitized Chemotherapy Combined with Gene Therapy to Nasopharyngeal Carcinoma.

Co-delivery of Sirna and Hypericin into Cancer Cells by Hyaluronic Acid Modified PLGA-PEI Nanoparticles.

Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy

Multifunctional Magnetic Co-Delivery System Coated with Polymer Mpeg-Pll-fa for Nasopharyngeal Cancer Targeted Therapy and MR Imaging.

A Glutathione-Sensitive Cationic Polymer Delivery of CRISPR-Cas9 RNA Plasmid for Targeting Nasopharyngeal Carcinoma Gene Therapy.

A Cationic Polymeric Prodrug with Chemotherapeutic Self-Sensibilization Co-Delivering MMP-9 Shrna Plasmid for a Combined Therapy to Nasopharyngeal Carcinoma

Honokiol-loaded Polymeric Nanoparticles: an Active Targeting Drug Delivery System for the Treatment of Nasopharyngeal Carcinoma.

Tumor Therapeutics Via Highly Efficient Mirna Delivery to Human Nasopharyngeal Cancer Cells by Multifunctional Magnetic Nanoparticles

Non-Cationic RGD-Containing Protein Nanocarrier for Tumor-Targeted siRNA Delivery

Therapeutic Delivery Of Sirna Silencing Hif-1 Alpha With Micellar Nanoparticles Inhibits Hypoxic Tumor Growth

Systemic Delivery of Sirna by Hyaluronan-Functionalized Calcium Phosphate Nanoparticles for Tumor-Targeted Therapy

The Ph-Triggered Triblock Nanocarrier Enabled Highly Efficient Sirna Delivery for Cancer Therapy

Stimuli-Responsive and Highly Penetrable Nanoparticles As a Multifunctional Nanoplatform for Boosting Nonsmall Cell Lung Cancer Sirna Therapy

Multi-functional Self-Assembled Nanoparticles for Pvegf-Shrna Loading and Anti-Tumor Targeted Therapy.

Pegylated Carboxymethyl Chitosan/Calcium Phosphate Hybrid Anionic Nanoparticles Mediated Htert Sirna Delivery for Anticancer Therapy

Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer

Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows in vitro and in vivo antitumor efficacy toward the treatment of nasopharyngeal cancer cells

Enhanced Nose-to-brain Delivery of Sirna Using Hyaluronan-Enveloped Nanomicelles for Glioma Therapy

Biocompatible Co-Loading Vehicles for Delivering Both Nanoplatin Cores and Sirna to Treat Hepatocellular Carcinoma